Document is current
Any future updates will be listed below
-
Authors
Shapley-Quinn, Mary Kate https://orcid.org/0000-0001-9805-3132
Tenza, Siyanda
Jensen, Destry
Tauya, Thelma
Mampuru, Lydia
Etima, Juliane https://orcid.org/0000-0002-5879-6000
Kemigisha, Doreen
Atujuna, Millicent https://orcid.org/0000-0003-1287-2634
Soto-Torres, Lydia
Johnson, Sherri
Mpongo, Nombeko
Mhlanga, Nomsa
Ngure, Kenneth https://orcid.org/0000-0002-8062-0933
van der Straten, Ariane https://orcid.org/0000-0001-8536-648X
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707)
- License Information
-
More Information
Article History
Accepted: 7 September 2024
First Online: 30 September 2024
Declarations
:
: The authors have no competing interests to declare that are relevant to the content of this article.
: The study protocol was approved by the Institutional Review Board or Ethics Committee at each site. The study was overseen by the regulatory infrastructure of the Division of AIDS (DAIDS) and the Microbicide Trials Network (MTN).
: All participants provided written informed consent for study participation and confirmed consent verbally for qualitative activities and the recording thereof prior to participating in qualitative interviews.
